SHALLCROSS STEVEN A (CEO and CFO) purchased 1000.0% of their position (100K shares) of THERIVA BIOLOGICS, INC. on the open market
Open‑market purchase worth $43.7K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 1/3/2023ACC: 0001104659-23-000023
DirectorOfficer· CEO and CFO
Since Dec 2018
+100K
Net shares
Net buyer
$43.7K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
100K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+100K
Price / share
$0.44
Trade value
$43.70K
% of position
1000.0%
12/29/2022
10K→110K
Total
Net shares
+100K
Net value
$43.70K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/29/2022 | P · Purchase | +100K | $0.44 | $43.70K | 1000.0% | 10K | 110K |
| Total | +100K | $43.70K | ||||||
Derivative Transactions0
No derivative transactions reported